These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16699267)
21. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169 [TBL] [Abstract][Full Text] [Related]
22. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Farthing MJ Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922 [TBL] [Abstract][Full Text] [Related]
23. Development of peripheral opioid antagonists' new insights into opioid effects. Moss J; Rosow CE Mayo Clin Proc; 2008 Oct; 83(10):1116-30. PubMed ID: 18828971 [TBL] [Abstract][Full Text] [Related]
24. Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use. Senagore AJ; Bauer JJ; Du W; Techner L Surgery; 2007 Oct; 142(4):478-86. PubMed ID: 17950339 [TBL] [Abstract][Full Text] [Related]
25. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Delaney CP; Weese JL; Hyman NH; Bauer J; Techner L; Gabriel K; Du W; Schmidt WK; Wallin BA; Dis Colon Rectum; 2005 Jun; 48(6):1114-25; discussion 1125-6; author reply 1127-9. PubMed ID: 15906123 [TBL] [Abstract][Full Text] [Related]
35. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gershon MD; Tack J Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888 [TBL] [Abstract][Full Text] [Related]
36. Effect of the peripherally selective kappa-opioid agonist, asimadoline, on adjuvant arthritis. Binder W; Walker JS Br J Pharmacol; 1998 Jun; 124(4):647-54. PubMed ID: 9690855 [TBL] [Abstract][Full Text] [Related]
37. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Camilleri M Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696 [No Abstract] [Full Text] [Related]
38. Opioids and the gut: pharmacology and current clinical experience. De Schepper HU; Cremonini F; Park MI; Camilleri M Neurogastroenterol Motil; 2004 Aug; 16(4):383-94. PubMed ID: 15305992 [TBL] [Abstract][Full Text] [Related]
39. Central effect of mu-opioid agonists on antral motility in conscious rats. Tsuchida D; Fukuda H; Koda K; Miyazaki M; Pappas TN; Takahashi T Brain Res; 2004 Oct; 1024(1-2):244-50. PubMed ID: 15451387 [TBL] [Abstract][Full Text] [Related]
40. Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials. Valentin N; Acosta A; Camilleri M Expert Opin Investig Drugs; 2015 Jun; 24(6):769-79. PubMed ID: 25971881 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]